Form 4 for AGIO AGIOS PHARMACEUTICALS, INC.
Accepted 2023-02-15 00:00:00 ET · period of report 2023-02-13 · accession 0001439222-23-000020 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-15 | 2023-02-13 | AGIO | Schenkein David P | Dir | M - OptEx | $9.05 | +20.0K | 137.9K | +17% | +$181.0K |
| D | 2023-02-15 | 2023-02-13 | AGIO | Schenkein David P | Dir | S - Sale+OE | $28.62 | -20.0K | 117.9K | -15% | -$572.4K |
| D | 2023-02-15 | 2023-02-13 | AGIO | Schenkein David P | Dir | M - OptEx | $0.00 | -20.0K | 76.4K | -21% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common stock | 2023-02-13 | M | A | 20,000 | $9.05 | 137,879 | D | — | — | |
| 2 | Common | Common stock | 2023-02-13 | S | D | 20,000 | $28.62 | 117,879 | D | — | — | (F3) The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $28.25 to $28.94. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. |
| 3 | Derivative | Stock option (right to buy) | 2023-02-13 | M | D | 20,000 | $0.00 | 76,363 | D | $9.05 · — to 2023-04-29 | 20,000 Common stock | (F6) This option was originally granted on April 30, 2013 for the purchase of 136,363 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 68,181 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 68,182 shares. |